How AML becomes resistant to treatment over time
Architecture and Trajectory of Acquired Resistance to Therapy in AML
Researchers are mapping how acute myeloid leukemia (AML) cells and the bone marrow environment change during and after treatment to find better drug combinations for people with AML.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11180337 on NIH RePORTER |
What this research studies
From a patient's perspective, this program follows AML cells and bone marrow samples over time to see how the disease adapts and avoids drugs. The team uses large-scale genetic experiments (including CRISPR screens), studies of tumor–stromal and immune cell interactions, and tests of drug combinations in lab models and patient-derived samples. The group has built one of the largest AML functional genomics datasets and shares data publicly to speed discoveries. Their work is designed to feed findings into clinical trials that could try new combination therapies.
Who could benefit from this research
Good fit: Ideal candidates are people diagnosed with acute myeloid leukemia who can provide blood or bone marrow samples and who may be eligible for related clinical trials.
Not a fit: People without AML or those who cannot provide blood or bone marrow samples or are ineligible for trial enrollment are unlikely to directly benefit from participation.
Why it matters
Potential benefit: If successful, this work could identify drug combinations that prevent relapse and improve long-term survival for people with AML.
How similar studies have performed: Previous studies using genomic profiling, functional screens, and microenvironment studies have led to new treatment ideas and clinical trials, but durable cures for relapsed AML remain uncommon.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Tyner, Jeffrey Wallace — Oregon Health & Science University
- Study coordinator: Tyner, Jeffrey Wallace
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.